Table 3 Budget impact analysis results
Year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
Iran population | 85,345,667 | 86,369,815 | 87,406,253 | 88,455,128 | 89,516,589 |
Number of patients of MM | 4267 | 4318 | 4370 | 4423 | 4476 |
Number of patients of MM with adjusted death rate | 3456 | 3498 | 3540 | 3582 | 3625 |
Total number of MM who deserve to receive DRd or KRd | 691 | 700 | 708 | 716 | 725 |
KRD market share | 0.95 | 0.9 | 0.85 | 0.8 | 0.75 |
Daratumumab market share | 0.05 | 0.1 | 0.15 | 0.2 | 0.25 |
Scenario 1 (without DRd) | 10,258,397 | 10,381,497 | 10,506,457 | 10,632,438 | 10,759,734 |
Scenario 2 (with DRd) | 10,656,889 | 11,188,046 | 11,730,407 | 12,284,193 | 12,849,570 |
Financial impact | 398,492 | 806,549 | 1,223,950 | 1,651,755 | 2,089,836 |
Financial impact% | 3% | 7% | 12% | 16% | 19% |